TY - JOUR
T1 - Biologic registries in rheumatology
T2 - Lessons learned and expectations for the future
AU - Elkayam, Ori
AU - Pavelka, Karel
N1 - Funding Information:
Editorial/medical writing support was provided by WC Hatch at ACUMED and was funded by Pfizer Inc . No financial support was provided to the authors for this work.
PY - 2012/12
Y1 - 2012/12
N2 - Biologic registries have been established in several countries to supplement information obtained from randomized controlled trials with regards to the efficacy and safety of biologic agents in the treatment of rheumatic diseases. The unique features that characterized several of the cohorts included in these registries allow analysis to answer certain research questions such as the relation of biologic use and the incidence of tuberculosis, lymphoma, or its effect on pregnancy. The availability of such population-specific registries in Europe with different biologic uses, comorbidity patterns, and various socio-demographic and geographic factors provides real-life information valuable to clinical practice in the management of rheumatic diseases. Certain challenges including logistics, methodologies, human, and financial resources, remain in the implementation and maintenance of registries and steps have been proposed to address these issues.
AB - Biologic registries have been established in several countries to supplement information obtained from randomized controlled trials with regards to the efficacy and safety of biologic agents in the treatment of rheumatic diseases. The unique features that characterized several of the cohorts included in these registries allow analysis to answer certain research questions such as the relation of biologic use and the incidence of tuberculosis, lymphoma, or its effect on pregnancy. The availability of such population-specific registries in Europe with different biologic uses, comorbidity patterns, and various socio-demographic and geographic factors provides real-life information valuable to clinical practice in the management of rheumatic diseases. Certain challenges including logistics, methodologies, human, and financial resources, remain in the implementation and maintenance of registries and steps have been proposed to address these issues.
KW - Biological therapy
KW - Europe
KW - Registries
KW - Review
KW - Rheumatoid arthritis
KW - TNFR-Fc fusion protein
UR - http://www.scopus.com/inward/record.url?scp=84870242760&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2012.05.009
DO - 10.1016/j.autrev.2012.05.009
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 22683382
AN - SCOPUS:84870242760
SN - 1568-9972
VL - 12
SP - 329
EP - 336
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 2
ER -
